Howard Kaufman

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. doi request reprint OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
    Howard L Kaufman
    The Tumor Immunology Laboratory and Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA
    Future Oncol 6:941-9. 2010
  2. pmc First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
    Neil L Berinstein
    Sunnybrook Health Sciences Center, Toronto, ON, Canada
    J Transl Med 10:156. 2012
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  4. pmc Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression
    Xiulong Xu
    Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA
    BMC Cancer 11:194. 2011
  5. doi request reprint Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    Howard L Kaufman
    Department of Surgery, Medicine and Immunology, Rush University Medical Center, Chicago, IL, USA
    Ann Surg Oncol 17:718-30. 2010

Collaborators

  • Neil L Berinstein
  • Kunle Odunsi
  • Xiulong Xu
  • Bernard A Fox
  • Genevieve M Weir
  • Michael A Morse
  • Gurkamal Chatta
  • Marianne M Stanford
  • John J Nemunaitis
  • Lisa D MacDonald
  • Leeladhar Sammatur
  • Marc Mansour
  • Mohan Karkada
  • Rita Nigam
  • Robert O Dillman
  • Pamela S Ohashi
  • Kohzoh Imai
  • Samir N Khleif
  • Giorgio Parmiani
  • Jon M Wigginton
  • Graham Pawelec
  • Wenru Song
  • Tanja de Gruijl
  • James H Finke
  • Lisa H Butterfield
  • Xuetao Cao
  • Gerd Ritter
  • Beatrix Kotlan
  • Michael J Mastrangelo
  • Ronald B Herberman
  • Per thor Straten
  • Brad Nelson
  • Carl H June
  • Giuseppe Masucci
  • Cornelius Melief
  • Janet Plate
  • Elizabeth M Jaffee
  • Hyam I Levitsky
  • Jirina Bartunkova
  • Michele Maio
  • Jared A Gollob
  • Pedro J Romero
  • Ernest Borden
  • Lindy G Durrant
  • Marij Jp Welters
  • Dolores J Schendel
  • Michael Papamichail
  • Patrick Hwu
  • William E Carson
  • Leif Hakansson
  • Michael I Nishimura
  • Paul von Hoegen
  • Christoph Huber
  • Steinar Aamdal
  • James P Allison
  • Richard A Prinz
  • F Stephen Hodi
  • Harry Dolstra
  • Thomas F Gajewski
  • Ena Wang
  • Paolo Gattuso
  • Harpreet Singh-Jasuja
  • Hiroshi Shiku
  • Sylvia Janetzki
  • Robert Rees
  • Fabio Grizzi
  • Michael T Lotze
  • Koji Kawakami
  • William J Murphy
  • Jerome Galon
  • Michael B Atkins
  • Guido Kroemer
  • Thomas Spies
  • Alfred E Chang
  • Tara Withington
  • Ignacio Melero
  • Laurence Zitvogel
  • Lloyd J Old
  • Paolo Antonio Ascierto
  • A Raja Choudhury
  • Barbara Seliger
  • Weihua Xiao
  • Ulrich Keilholtz
  • Cristina Maccalli
  • Zhigang Tian
  • Padmanee Sharma
  • Neil Berinstein
  • Cecile Gouttefangeas
  • Dainius Characiejus
  • Francesco M Marincola

Detail Information

Publications5

  1. doi request reprint OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
    Howard L Kaufman
    The Tumor Immunology Laboratory and Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA
    Future Oncol 6:941-9. 2010
    ..The rationale, study design, end points and future development of the Oncovex(GM-CSF) Pivotal Trial in Melanoma (OPTIM) trial are discussed in this article...
  2. pmc First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
    Neil L Berinstein
    Sunnybrook Health Sciences Center, Toronto, ON, Canada
    J Transl Med 10:156. 2012
    ..Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-0907...
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  4. pmc Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression
    Xiulong Xu
    Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA
    BMC Cancer 11:194. 2011
    ..In this study, we sought to study MICA/B expression in pancreatic cancer and to determine whether and how genotoxic drugs such as gemcitabine can affect MICA/B expression and natural killer cytotoxity...
  5. doi request reprint Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    Howard L Kaufman
    Department of Surgery, Medicine and Immunology, Rush University Medical Center, Chicago, IL, USA
    Ann Surg Oncol 17:718-30. 2010
    ..The work reported herein was performed to better characterize the effect of vaccination on local and distant antitumor immunity...